文献速递类风湿关节炎其他结缔组织病

DMARD治疗与全身炎症对类风湿关节炎合并间质性肺病患者全因死亡率的影响:德国RABBIT登记队列研究

Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register.
PubMed 文献 · RMD Open · 2024-04-04

基于德国RABBIT登记中381例类风湿关节炎合并间质性肺病(RA-ILD)患者、1258人年观察和2.6年中位随访,97例(25.5%)死亡。炎症生物标志物升高与死亡率显著相关,未接受DMARD治疗者死亡风险约为接受任何DMARD治疗者的2倍(aHR 2.03,95%CI 1.23至3.35);非TNFi生物制剂联合JAKi对比TNFi的aHR为0.56(95%CI 0.33至0.97)。

要点

  • 炎症生物标志物升高与RA-ILD患者死亡率显著相关,而关节肿胀数和压痛数无显著关联。
  • 未接受DMARD治疗者死亡风险约为接受任何DMARD治疗者的2倍(aHR 2.03,95%CI 1.23至3.35)。
  • 非TNFi生物制剂联合JAKi对比TNFi的死亡aHR为0.56(95%CI 0.33至0.97)。

核心结论

  • 在RA-ILD患者中,炎症生物标志物升高和未接受DMARD治疗与死亡风险增加相关。
  • 非TNFi生物制剂可能为RA-ILD患者带来增强的治疗获益。

研究设计与样本

  • 从生物制剂登记RABBIT中选取类风湿关节炎合并间质性肺病(RA-ILD)患者。
  • 采用时变Cox回归分析临床指标与死亡率的关联。
  • DMARD影响分析采用两种方法:考虑累积暴露(治疗月数除以总月数)的Cox回归,以及以月度水平治疗暴露为时变变量的Cox回归作为主要方法。
  • 共纳入381例RA-ILD患者,观察1258人年,中位随访时长2.6年。

主要发现

  • 15566名参与者中识别出381例RA-ILD患者,97例(25.5%)死亡,其中34例(35.1%)死亡时未接受DMARD治疗。
  • 较高的炎症生物标志物与死亡率显著相关,而肿胀关节数和压痛关节数与死亡率无显著关联。
  • 对比TNFi,非TNFi生物制剂DMARD的死亡校正HR低于1但无统计学显著性,该结果在多项敏感性分析中稳定。
  • 非TNFi生物制剂联合JAKi对比TNFi的死亡aHR为0.56(95%CI 0.33至0.97)。
  • 未接受DMARD治疗对比接受任何DMARD治疗的死亡aHR为2.03(95%CI 1.23至3.35)。

关键数值与推荐

  • 非TNFi生物制剂联合JAKi对比TNFi的死亡aHR为0.56(95%CI 0.33至0.97)。
  • 未接受DMARD治疗对比接受任何DMARD治疗的死亡aHR为2.03(95%CI 1.23至3.35)。
  • 97例(25.5%)死亡患者中34例(35.1%)死亡时未接受DMARD治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). METHODS: Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated. The impact of DMARDs was analysed by (1) Cox regression considering cumulative exposure (ie, treatment months divided by total months) and (2) time-varying Cox regression as main approach (treatment exposures at monthly level). RESULTS: Out of 15 566 participants, 381 were identified as RA-ILD cases with 1258 person-years of observation and 2.6 years median length of follow-up. Ninety-seven patients (25.5%) died and 34 (35.1%) of these were not receiving DMARD therapy at the time of death. Higher inflammatory biomarkers but not swollen and tender joint count were significantly associated with mortality. Compared with tumour necrosis factor inhibitors (TNFi), non-TNFi biologic DMARDs (bDMARDs) exhibited adjusted HRs (aHRs) for mortality below 1, lacking statistical significance. This finding was stable in various sensitivity analyses. Joint aHR for non-TNFi biologics and JAKi versus TNFi was 0.56 (95% CI 0.33 to 0.97). Receiving no DMARD treatment was associated with a twofold higher mortality risk compared with receiving any DMARD treatment, aHR 2.03 (95% CI 1.23 to 3.35). CONCLUSIONS: Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with RA-ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Rudi T, Zietemann V, Meissner Y, et al. Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register. RMD Open. 2024. PMID: 38580343. doi:10.1136/rmdopen-2023-003789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。